Amgen's Repatha Reduces Death Risk by 20% in Heart Study
Amgen (AMGN) reported new findings from a pre-specified Phase 3 VESALIUS-CV trial analysis showing that its drug Repatha, when added to statins or other LDL cholesterol-lowering treatments, reduced the risk of death by 20% in high-risk adults without prior heart attacks or strokes. The results highlight Repatha's potential as an effective treatment for reducing cardiovascular mortality. The study focused on patients at elevated risk but who had not yet experienced a major cardiac event. This data could influence prescribing practices and expand the drug’s market, particularly among physicians seeking additional therapies to complement standard cholesterol-lowering regimens.
Tickers: $AMGN